Discovery of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase as Potential Anticancer Agents

Journal of Medicinal Chemistry

Volumn 54, Issue 7, 2011, Pages 2320-2330

  Charrier, Jean Damien ^a   Durrant, Steven J ^a   Golec, Julian M C ^a   Kay, David P ^a   Knegtel, Ronald M A ^a   MacCormick, Somhairle ^a   Mortimore, Michael ^a   O'Donnell, Michael E ^a   Pinder, Joanne L ^a   Reaper, Philip M ^a   Rutherford, Alistair P ^a   Wang, Paul S H ^a   Young, Stephen C ^a   Pollard, John R ^a  

^a VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINO 6 [4 [[1 (DIMETHYLAMINO)PROPAN 2 YL]SULFONYL]PHENYL] N PHENYLPYRAZINE 2 CARBOXAMIDE; AMINOPYRAZINE DERIVATIVE; ANTINEOPLASTIC AGENT; ATR PROTEIN; PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; ENZYME INHIBITION; IC 50; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; CATALYTIC DOMAIN; DRUG DISCOVERY; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PYRAZINES; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; SULFONES;

EID: 79953773734     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm101488z     Document Type: Article

References (54)

1. Einhorn, L. H. Curing metastatic testicular cancer Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 4592-4595 (Pubitemid 34286029)
2. Longley, D. B.; Johnston, P. G. Molecular mechanisms of drug resistance J. Pathol. 2005, 205, 275-292 (Pubitemid 40227997)
3. Borst, P.; Rottenberg, S.; Jonkers, J. How do real tumors become resistant to cisplatin Cell Cycle 2008, 7, 1353-1359 (Pubitemid 351872573)
4. Oliver, T. G.; Mercer, K. L.; Sayles, L. C.; Burke, J. R.; Mendus, D.; Lovejoy, K. S.; Cheng, M.-H.; Subramanian, A.; Mu, D.; Powers, S.; Crowley, D.; Bronson, R. T.; Whittaker, C. A.; Bhutkar, A.; Lippard, S. J.; Golub, T.; Thomale, J.; Jacks, T.; Sweet-Cordero, E. A. Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer Genes Dev. 2010, 24, 837-852
5. Olaussen, K. A.; Dunant, A.; Fouret, P.; Brambilla, E.; André, F.; Haddad, V.; Taranchon, E.; Filipits, M.; Pirker, R.; Popper, H. H.; Stahel, R.; D., M.; Sabatier, L.; Pignon, J.-P.; Tursz, T.; Le Chevalier, T.; Soria, J.-C. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy N. Engl. J. Med. 2006, 355, 983-991 (Pubitemid 44343542)
6. Jackson, S. P.; Bartek, J. The DNA-damage response in human biology and disease Nature 2009, 461, 1071-1078
7. Kastan, M. B.; Bartek, J. Cell-cycle checkpoints and cancer Nature 2004, 432, 316-323 (Pubitemid 39551659)
8. Cimprich, K. A.; Cortez, D. ATR: An essential regulator of genome integrity Nat. Rev. Mol. Cell Biol. 2008, 9, 616-627 (Pubitemid 352032926)
9. Jiang, H.; Reinhardt, H. C.; Bartkova, J.; Tommiska, J.; Blomqvist, C.; Nevanlinna, H.; Bartek, J.; Yaffe, M. B.; Hemann, M. T. The combined status of ATM and p53 link tumor development with therapeutic response Genes Dev. 2009, 23, 1895-1909
10. Ding, L.; Getz, G.; Wheeler, D. A.; Mardis, E. R.; McLellan, M. D.; Cibulskis, K.; Sougnez, C.; Greulich, H.; Muzny, D. M.; Morgan, M. B.; Fulton, L.; Fulton, R. S.; Zhang, Q.; Wendl, M. C.; Lawrence, M. S.; Larson, D. E.; Chen, K.; Dooling, D. J.; Sabo, A.; Hawes, A. C.; Shen, H.; Jhangiani, S. N.; Lewis, L. R.; Hall, O.; Zhu, Y.; Mathew, T.; Ren, Y.; Yao, J.; Scherer, S. E.; Clerc, K.; Metcalf, G. A.; Ng, B.; Milosavljevic, A.; Gonzalez-Garay, M. L.; Osborne, J. R.; Meyer, R.; Shi, X.; Tang, Y.; Koboldt, D. C.; Lin, L.; Abbott, R.; Miner, T. L.; Pohl, C.; Fewell, G.; Haipek, C.; Schmidt, H.; Dunford-Shore, B. H.; Kraja, A.; Crosby, S. D.; Sawyer, C. S.; Vickery, T.; Sander, S.; Robinson, J.; Winckler, W.; Baldwin, J.; Chirieac, L. R.; Dutt, A.; Fennell, T.; Hanna, M.; Johnson, B. E.; Onofrio, R. C.; Thomas, R. K.; Tonon, G.; Weir, B. A.; Zhao, X.; Ziaugra, L.; Zody, M. C.; Giordano, T.; Orringer, M. B.; Roth, J. A.; Spitz, M. R.; Wistuba, I. I.; Ozenberger, B.; Good, P. J.; Chang, A. C.; Beer, D. G.; Watson, M. A.; Ladanyi, M.; Broderick, S.; Yoshizawa, A.; Travis, W. D.; Pao, W.; Province, M. A.; Weinstock, G. M.; Varmus, H. E.; Gabriel, S. B.; Lander, E. S.; Gibbs, R. A.; Meyerson, M.; Wilson, R. K. Somatic mutations affect key pathways in lung adenocarcinoma Nature 2008, 455, 1069-1075
11. Bolt, J.; Vo, Q. N.; Kim, W. J.; McWhorter, A. J.; Thomson, J.; Hagensee, M. E.; Friedlander, P.; Brown, K. D.; Gilbert, J. The ATM/p53 pathway is commonly targeted for inactivation in squamous cell carcinoma of the head and neck (SCCHN) by multiple molecular mechanisms Oral Oncol. 2005, 41, 1013-1020 (Pubitemid 41434067)
12. Greenman, C.; Stephens, P.; Smith, R.; Dalgliesh, G. L.; Hunter, C.; Bignell, G.; Davies, H.; Teague, J.; Butler, A.; Stevens, C.; Edkins, S.; O'Meara, S.; Vastrik, I.; Schmidt, E. E.; Avis, T.; Barthorpe, S.; Bhamra, G.; Buck, G.; Choudhury, B.; Clements, J.; Cole, J.; Dicks, E.; Forbes, S.; Gray, K.; Halliday, K.; Harrison, R.; Hills, K.; Hinton, J.; Jenkinson, A.; Jones, D.; Menzies, A.; Mironenko, T.; Perry, J.; Raine, K.; Richardson, D.; Shepherd, R.; Small, A.; Tofts, C.; Varian, J.; Webb, T.; West, S.; Widaa, S.; Yates, A.; Cahill, D. P.; Louis, D. N.; Goldstraw, P.; Nicholson, A. G.; Brasseur, F.; Looijenga, L.; Weber, B. L.; Chiew, Y. E.; DeFazio, A.; Greaves, M. F.; Green, A. R.; Campbell, P.; Birney, E.; Easton, D. F.; Chenevix-Trench, G.; Tan, M. H.; Khoo, S. K.; Teh, B. T.; Yuen, S. T.; Leung, S. Y.; Wooster, R.; Futreal, P. A.; Stratton, M. R. Patterns of somatic mutation in human cancer genomes Nature 2007, 446, 153-158 (Pubitemid 46398669)
13. Halazonetis, T. D.; Gorgoulis, V. G.; Bartek, J. An oncogene-induced DNA damage model for cancer development Science 2008, 319, 1352-1355 (Pubitemid 351354863)
14. Nghiem, P.; Park, P. K.; Kim, Y.; Vaziri, C.; Schreiber, S. L. ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 9092-9097 (Pubitemid 32743874)
15. Nghiem, P.; Park, P. K.; Kim, Y. Y. S.; Desai, B. N.; Schreiber, S. L. ATR is not required for p53 activation but synergizes with p53 in the replication checkpoint J. Biol. Chem. 2002, 277, 4428-4434 (Pubitemid 34968710)
16. Reinhardt, H. C.; Jiang, H.; Hemann, M. T.; Yaffe, M. B. Exploiting synthetic lethal interactions for targeted cancer therapy Cell Cycle 2009, 8, 3112-3119
17. Audeh, M. W.; Carmichael, J.; Penson, R. T.; Friedlander, M.; Powell, B.; Bell-McGuinn, K. M.; Scott, C.; Weitzel, J. N.; Oaknin, A.; Loman, N.; Lu, K.; Schmutzler, R. K.; Matulonis, U.; Wickens, M.; Tutt, A. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial Lancet 2010, 376, 245-251
18. Tutt, A.; Robson, M.; Garber, J. E.; Domchek, S. M.; Audeh, M. W.; Weitzel, J. N.; Friedlander, M.; Arun, B.; Loman, N.; Schmutzler, R. K.; Wardley, A.; Mitchell, G.; Earl, H.; Wickens, M.; Carmichael, J. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial Lancet 2010, 376, 235-244
19. Hickson, I.; Zhao, Y.; Richardson, C. J.; Green, S. J.; Martin, N. M. B.; Orr, A. I.; Reaper, P. M.; Jackson, S. P.; Curtin, N. J.; Smith, G. C. M. Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM Cancer Res. 2004, 64, 9152-9159 (Pubitemid 39665530)
20. Griffin, R. J.; Fontana, G.; Golding, B. T.; Guiard, S.; Hardcastle, I. R.; Leahy, J. J. J.; Martin, N.; Richardson, C.; Rigoreau, L.; Stockley, M.; Smith, G. C. M. Selective Benzopyranone and Pyrimido[2,1-a]isoquinolin-4-one Inhibitors of DNA-Dependent Protein Kinase: Synthesis, Structure-Activity Studies, and Radiosensitization of a Human Tumor Cell Line in Vitro J. Med. Chem. 2005, 48 (2) 569-585 (Pubitemid 40139799)
21. Zabludoff, S. D.; Deng, C.; Grondine, M. R.; Sheehy, A. M.; Ashwell, S.; Caleb, B. L.; Green, S.; Haye, H. R.; Horn, C. L.; Janetka, J. W.; Liu, D.; Mouchet, E.; Ready, S.; Rosenthal, J. L.; Queva, C.; Schwartz, G. K.; Taylor, K. J.; Tse, A. N.; Walker, G. E.; White, A. M. AZD a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies Mol. Cancer Ther. 2008, 7 (9) 2955-2966
22. Sarkaria, J. N.; Busby, E. C.; Tibbetts, R. S.; Roos, P.; Taya, Y.; Karnitz, L. M.; Abraham, R. T. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine Cancer Res. 1999, 59, 4375-4382 (Pubitemid 29418757)
23. Nishida, H.; Tatewaki, N.; Nakajima, Y.; Magara, T.; Ko, K. M.; Hamamori, Y.; Konishi, T. Inhibition of ATR protein kinase activity by schisandrin B in DNA damage response Nucleic Acids Res. 2009, 37, 5678-5689
24. Wagner, J. M.; Kaufmann, S. H. Prospects for the Use of ATR Inhibitors to Treat Cancer Pharmaceuticals 2010, 3, 1311-1334
25. Charrier, J.-D.; Durrant, S.; Kay, D.; O'Donnell, M.; Knegtel, R.; Maccormick, S.; Pinder, J.; Virani, A.; Young, S.; Binch, H.; Cleveland, T.; Fanning, L. T. D.; Hurley, D.; Joshi, P.; Sheth, U.; Silina, A. Preparation of pyrazine compounds as inhibitors of ATR kinase for use in treating disease and as biological tools; WO 2010054398.
26. Charrier, J.-D.; Durrant, S.; Kay, D.; Knegtel, R.; MacCormick, S.; Mortimore, M.; O'Donnell, M.; Pinder, J.; Rutherford, A.; Virani, A. N.; Young, S.; Reaper, P. M. Pyrazine derivatives useful as inhibitors of ATR kinase and their preparation and use in the treatment of diseases; WO 2010071837.
27. Foote, K. M.; Nissink, J.; Wilhelmus, M. Pyrimidinyl indole derivatives, and their preparation and use for prevention or treatment of tumors which are sensitive to inhibition of ATR kinase cancer; WO 2010073034.
28. Ellingson, R. C.; Henry, R. L. Pyrazine chemistry. IV. Bromination of 2-amino-3-carbomethoxypyrazine J. Am. Chem. Soc. 1949, 71, 2798-800
29. Bonnefous, C.; Vernier, J.-M.; Hutchinson, J. H.; Chung, J.; Reyes-Manalo, G.; Kamenecka, T. Dipyridyl amides: Potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonists Bioorg. Med. Chem. Lett. 2005, 15 (4) 1197-1200 (Pubitemid 40458673)
30. Bonnefous, C.; Kamenecka, T.; Vernier, J.-M. Preparation of bipyridyl amides as modulators of metabotropic glutamate receptor-5; WO 2005079802.
31. Yuan, J.; Guo, Q.; Zhao, H.; Hu, S.; Whitehouse, D.; Fringle, W.; Mao, J.; Maynard, G.; Hammer, J.; Wustrow, D.; Li, H. Preparation of substituted heteroaryl CB1 antagonists; WO 2006113704.
32. Rushton, L.; Winter, J. J. G. Pyrazine derivatives as Axl and C-Met receptor enzyme inhibitors and their preparation and use in the treatment of tumors; WO 2009007390.
33. Dunwell, D. W.; Evans, D.; Hicks, T. A. Synthesis and antiinflammatory activity of some 2-heteroaryl-a -methyl-5-benzoxazoleacetic acids J. Med. Chem. 1975, 18 (11) 1158-1159
34. Sun, B.; Guan, J.-X.; Xu, L.; Yu, B.-L.; Jiang, L.; Kou, J.-F.; Wang, L.; Ding, X.-D.; Chao, H.; Ji, L.-N. DNA Condensation Induced by Ruthenium(II) Polypyridyl Complexes [Ru(bpy)2(PIPSH)]2+ and [Ru(bpy)2(PIPNH)]2 Inorg. Chem. 2009, 48 (11) 4637-4639
35. Holljes, E. L., Jr.; Wagner, E. C. Some Reactions of Nitriles as Acid Anammonides J. Org. Chem. 1944, 9 (1) 31-49
36. Nakamura, H.; Takeuchi, D.; Murai, A. Synthesis of 5- and 3,5-substituted 2-aminopyrazines by Pd mediated Stille coupling Synlett 1995, 12, 1227-1228
37. Adamczyk, M.; Akireddy, S. R.; Johnson, D. D.; Mattingly, P. G.; Pan, Y.; Reddy, R. E. Synthesis of 3,7-dihydroimidazo[1,2a]pyrazine-3-ones and their chemiluminescent properties Tetrahedron 2003, 59 (41) 8129-8142 (Pubitemid 37163606)
38. Ward, I. M.; Chen, J. Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational stress J. Biol. Chem. 2001, 276, 47759-47762
39. Williams, R.; Berndt, A.; Miller, S.; Hon, W. C.; Zhang, X. Form and flexibility in phosphoinositide 3-kinases Biochem. Soc. Trans. 2009, 37 (4) 615-626
40. PDB entry 1E8Z: Walker, E. H.; Pacold, M. E.; Perisic, O.; Stephens, L.; Hawkins, P. T.; Wymann, M. P.; Williams, R. L. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine Mol. Cell 2000, 6 (4) 909-919
41. Sibanda, B. L.; Chirgadze, D. Y.; Blundell, T. L. Crystal structure of DNA-PKcs reveals a large open-ring cradle comprised of HEAT repeats Nature 2010, 463, 118-122
42. Zhang, D.; Wang, Z.; Xu, W.; Sun, F.; Tang, L.; Wang, J. Design, synthesis and antibacterial activity of novel actinonin derivatives containing benzimidazole heterocycles Eur. J. Med. Chem. 2009, 44 (5) 2202-2210
43. 50]) of an enzymatic reaction Biochem. Pharmacol. 1973, 22, 3099-3108
44. Cortez, D.; Guntuku, S.; Qin, J.; Elledge, S. J. ATR and ATRIP: partners in checkpoint signaling Science 2001, 294, 1713-1716 (Pubitemid 33104841)
45. Casper, A. M.; Nghiem, P.; Arlt, M. F.; Glover, T. W. ATR regulates fragile site stability Cell 2002, 111, 779-789 (Pubitemid 36106400)
46. Sorensen, C. S.; Syljuasen, R. G.; Lukas, J.; Bartek, J. ATR, Claspin and the Rad9-Rad1-Hus1 complex regulate Chk1 and Cdc25A in the absence of DNA damage Cell Cycle 2004, 3, 941-945 (Pubitemid 40179476)
47. Hurley, P. J.; Wilsker, D.; Bunz, F. Human cancer cells require ATR for cell cycle progression following exposure to ionizing radiation Oncogene 2007, 26, 2535-2542 (Pubitemid 46632006)
48. Wilsker, D.; Bunz, F. Loss of ataxia telangiectasia mutated- and Rad3-related function potentiates the effects of chemotherapeutic drugs on cancer cell survival Mol. Cancer Ther. 2007, 6, 1406-1413 (Pubitemid 46712004)
49. Cliby, W. A.; Roberts, C. J.; Cimprich, K. A.; Stringer, C. M.; Lamb, J. R.; Schreiber, S. L.; Friend, S. H. Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints EMBO J. 1998, 17, 159-169 (Pubitemid 28041057)
50. Kim, W. J.; Vo, Q. N.; Shrivastav, M.; Lataxes, T. A.; Brown, K. D. Aberrant methylation of the ATM promoter correlates with increased radiosensitivity in a human colorectal tumor cell line Oncogene 2002, 21, 3864-3871 (Pubitemid 34620854)
51. Takemura, H; Rao, V. A.; Sordet, O.; Furuta, T.; Miao, Z.-H.; Meng, L.; Zhang, H.; Pommier, Y. Defective Mre11-dependent activation of Chk2 by ataxia telangiectasia mutated in colorectal carcinoma cells in response to replication-dependent DNA double strand breaks J. Biol. Chem. 2006, 281, 30814-30823 (Pubitemid 44582136)
52. Prichard, M. N.; Prichard, L. E.; Shipman, C., Jr. Strategic design and three-dimensional analysis of antiviral drug combinations Antimicrob. Agents Chemother. 1993, 37, 540-545 (Pubitemid 23072600)
53. Unsal-Kacmaz, K.; Makhov, A. M.; Griffith, J. D.; Sancar, A. Preferential binding of ATR protein to UV-damaged DNA Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 6673-6678 (Pubitemid 34526191)
54. Pitt, A. M.; Lee, C. High throughput screening protein kinase assays optimized for reaction, binding, and detection totally within a 96-well plate J. Biomol. Screening 1996, 1, 47-51 (Pubitemid 126677154)